ST 113
Alternative Names: ST-113Latest Information Update: 03 Jan 2024
At a glance
- Originator Stuart Therapeutics
- Developer Glaukos Corporation; Stuart Therapeutics
- Class Anti-inflammatories; Eye disorder therapies; Peptide fragments
- Mechanism of Action Collagen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glaucoma